Exhibit 107

 

Calculation of Filing Fee Tables

 

Form F-1

 

Virax Biolabs Group Limited

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

  Security
Type
Security
Class
Title
Fee
Calculation
or Carry
Forward Rule
Amount
Registered(1)
Proposed
Maximum
Offering
Price Per
Unit
Maximum
Aggregate
Offering
Price(1)
Fee
Rate
Amount of
Registration
Fee
Newly Registered Securities
Fees to be
Paid
Equity Class A Ordinary
shares, par value
US$0.0001 per
share(5)
Rule 457(c) 1,944,784 $5.00 $9,723,920.00 0.0000927 $901.41
Fees Previously
Paid
Equity Class A Ordinary
shares, par value
US$0.0001 per
share(1)(2)
Rule 457(o)  1,380,000 $5.00 $6,000,000.00 0.0000927 $639.63
  Equity Underwriter’s
Warrants(2)(3)(4)
Rule 457(g) - - - - -
  Equity Class A Ordinary
shares underlying
Underwriter’s
Warrants(4)
Rule 457(g)  96,600 $5.00 $483,000.00 0.0000927 $44.78
  Total Offering Amounts $5.00 $16,206,920.00  0.0000927 $1,585.82
  Total Fees Previously Paid       $1,774.97
  Total Fee Offsets       $1,585.82
  Net Fee Due       -

 

(1)Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933 (the “Securities Act”), as amended. Includes the Class A Ordinary Shares that the underwriters have the option to purchase to cover any over-allotments.

 

(2)Pursuant to Rule 416 under the Securities Act, as amended, there is also being registered hereby such indeterminate number of additional Class A Ordinary Shares of the Registrant as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions.

 

(3)No fee required pursuant to Rule 457(g) under the Securities Act.

 

(4)Represents Class A Ordinary Shares underlying one or more warrants (the “Representative’s Warrants”) issuable to the representative of the several underwriters to purchase up to an aggregate of 10% of the Ordinary Shares sold in the offering at an exercise price equal to 110% of the public offering price. The Representative’s Warrants will be exercisable upon issuance, will have a cashless exercise provision and will terminate five years from the commencement of sales of the public offering.

 

(5)This Registration Statement also covers the resale under a separate resale prospectus (the “Resale Prospectus”) by selling stockholders of the Registrant of up to 1,887,343 Class A Ordinary Shares previously issued to the selling stockholders as named in the Resale Prospectus. Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended.